The global Heart Attack Diagnostics Market recorded a substantial size of USD 12.44 billion in 2021 and is anticipated to exhibit a robust compound annual growth rate (CAGR) of 8.0% throughout the projected period. The surge in heart attack occurrences, often accompanied by multiple instances of Coronary Artery Diseases (CAD), coupled with increased alcohol and cigarette consumption, emerges as pivotal factors poised to propel the growth of the heart attack diagnostics market in the foreseeable future. A study conducted by the National Heart Lung and Blood Institute on February 3, 2021, highlighted the escalating rates of deaths and disabilities due to cardiovascular diseases worldwide. In 2019 alone, an estimated 9.6 million men and 8.9 million women succumbed to cardiovascular diseases, with over six million falling within the 30 to 70 age bracket. The most significant number of fatalities was concentrated in densely populated countries like China, followed by India, Russia, the U.S., and Indonesia.
Advancements in technology and the integration of Artificial Intelligence (AI) into heart attack diagnostics are poised to be instrumental in fostering market revenue growth. AI systems are making notable strides in expediting time-consuming cardiovascular imaging tasks, encompassing anomaly detection, image segmentation, and patient selection. This is anticipated to lead to substantial cost reductions and enhanced value by employing AI in decision-making, image interpretation, and data collection. For instance, a breakthrough was achieved in April 2022 when researchers at the Yale School of Medicine developed an AI model that harnesses Electrocardiogram (ECG) images to diagnose heart rhythm and conduction disorders.
Get a free sample PDF of the report, visit @ https://www.reportsanddata.com/download-free-sample/4132
The heart attack diagnostics market is also anticipated to experience rapid growth due to consistent technological enhancements by major industry players in diagnostic imaging techniques. The availability of diverse imaging modalities is significantly aiding healthcare practitioners in accurately assessing individuals suspected of having coronary ischemia. Modalities like stress echocardiography, stress electrocardiography, myocardial perfusion imaging, and Magnetic Resonance Imaging (MRI) are providing both structural and functional insights into coronary stenosis, thus enhancing patient outcomes. Furthermore, the emergence of diagnostic pathways like Coronary Computed Tomography Angiography (CCTA) with perfusion, whole-heart magnetic resonance angiography, and CCTA fractional flow reserve is expected to fuel market expansion over the forecast period. Nonetheless, the lack of favorable reimbursement scenarios might exert some constraints on market growth. The American Heart Association (AHA) reported on May 6, 2020, that reimbursement laws in the U.S. primarily focus on medicare and are highly regulated, resulting in fragmented telehealth services reimbursement policies across states.
The market dynamics are further driven by key strategies, novel product launches, increased healthcare expenditure, major collaborations, partnerships, and escalated research and development activities. For instance, HeartFlow's merger with Longview Acquisition Corp. II in July 2021 paved the way for accelerated adoption and support for transforming heart disease care continuum. Top industry players are pursuing diverse strategies, focusing on innovative test creation, consistent technological progress, and product refinements. Abbott's introduction of the RX Implantable Cardiac Monitor (ICM) in May 2019 exemplifies this approach, offering heart rhythm tracking via heartbeat observation. Similarly, a breakthrough was achieved on February 3, 2022, when physician-scientists at Cedars-Sinai developed an AI-based tool to effectively differentiate between hypertrophic cardiomyopathy and cardiac amyloidosis.
However, the lack of skilled professionals for performing coronary artery catheterization procedures poses a restraint. The complexity of these procedures requires highly qualified and experienced healthcare personnel, and a shortage of such specialists, particularly in emerging countries, due to insufficient comprehensive training programs, is projected to limit market growth. Moreover, the ongoing COVID-19 pandemic has underscored the significance of heart attack diagnostics, leading to new developments and discoveries. Investments in advanced technologies to streamline workflows and efficiently manage time-consuming tasks have contributed to market revenue growth. AI has been utilized to comprehend the heart anatomy of COVID-19 patients, with algorithms speeding up cardio imaging and enabling accurate analysis of heart scans. ECG-capable smart wearables have been deployed to detect heart attacks in remote locations during the pandemic, leveraging AI-based algorithms to enhance sensitivity and identify cardiovascular issues before they become critical.
In terms of diagnostics procedures, the global heart attack diagnostics market is categorized into invasive and non-invasive procedures. The non-invasive procedures segment is projected to exhibit substantial growth, driven by the adoption of accurate and efficient cardiovascular imaging techniques like MRI, chest X-rays, electrocardiograms, and echocardiograms. These non-invasive methods are cost-effective and recommended by healthcare professionals, particularly as they avoid the use of intravenous contrast agents, pharmacological stress, or radiation. AI-driven non-invasive diagnostic tools are also making headway, contributing to an enhanced approach for diagnosing CAD.
Among the test types, the Electrocardiogram (ECG or EKG) segment dominated the market in 2021, owing to its widespread use in diagnosing cardiac disorders such as arrhythmia, congenital heart abnormalities, and coronary occlusion. Technological advancements have expanded the utility of ECG, with monitoring systems, event monitors, implantable loop recorders, cardiac telemetry, and ECG data management solutions contributing to its technological prowess and profitability. Additionally, the blood test segment is projected to achieve the fastest revenue CAGR during the forecast period. Rapid blood tests and enzyme-based diagnostic methods, such as the Troponin T diagnostic kit and Creatine Kinase MB Isoenzyme (CK-MB) diagnostic tool, are gaining significant traction in industrialized countries for their speed and accuracy. These tests yield results within a few hours, affording doctors crucial additional time to save patients' lives.
To know more about the latest insights of the report, visit @
https://www.reportsanddata.com/request-latest-insight/4132
The hospital segment accounts for a substantial revenue share in the end-use industry category due to the prevalence of diagnostic tests and procedures conducted within hospital settings for the diagnosis and treatment of cardiac issues. Hospitals are increasingly adopting advanced imaging and diagnostic technology to automate workflows and ensure accurate diagnoses. On the other hand, the ambulatory surgical centers segment is projected to experience the fastest revenue CAGR, attributed to a rising number of ambulatory clinic visits and cardiac imaging tests in these facilities for detecting heart-related disorders. Specialist surgeries like coronary angioplasty, performed in ambulatory surgical centers, further contribute to segment growth.
Regionally, North America commands the largest revenue share in the global heart attack diagnostics market, driven by escalating cases of CAD in the U.S. and Canada. The U.S. Centers for Disease Control reported that a person in the U.S. experiences a heart attack every 40 seconds, making it a costly treatment in American hospitals. The American Heart Association estimates that around 45% of the U.S. population will be afflicted by heart diseases by 2035, attributing this to factors like obesity, smoking, and sedentary lifestyles. The region benefits from a robust healthcare infrastructure and substantial investments in innovation.
In the Asia Pacific region, heart attack diagnostics market growth is projected to be steady between 2021 and 2030, driven by the high prevalence of heart diseases in certain areas, particularly India and China. In China, the incidence of heart attacks among individuals under 50 years of age has significantly risen over the past decade. Europe occupies a moderate share of the heart attack diagnostics market, characterized by a gradual increase in patients suffering from CAD and peripheral artery diseases. The European Union reports that cardiovascular attacks remain a major cause of death in the region. Technological advancements are fostering portability in diagnostic devices, such as Kings College London's blood test device designed to diagnose heart attacks rapidly and enhance diagnostic accuracy.
The competitive landscape of the global heart attack diagnostics market is moderately fragmented, with numerous key companies operating at both global and regional levels. These companies are actively involved in research and development initiatives, testing, and forming alliances to pioneer novel technologies. Some prominent industry players include General Electric Company, Siemens Healthcare GmbH, F. Hoffmann-La Roche Ltd., SCHILLER AG, Astra Zeneca, Hitachi Ltd., Koninklijke Philips N.V., Toshiba International Corporation, Abbott, Bionet, Midmark Corporation, and Bio-Rad Laboratories Inc. For instance, Royal Philips' acquisition of Cardiologs in November 2021 enhanced their cardiac monitoring and diagnostics offerings through innovative software technology and AI-driven ECG analysis. Similarly, Cleerly's introduction of power imaging technology based on AI in June 2021 aimed to provide a comprehensive view of cardiac health, offering improved insights compared to traditional indicators.
In conclusion, the global heart attack diagnostics market is undergoing substantial growth driven by factors such as the rising prevalence of heart attacks, advancements in technology, and the integration of AI. Key strategies, novel product launches, and collaborations are shaping the market landscape. The non-invasive procedures and Electrocardiogram (ECG or EKG) segments are anticipated to drive market growth, along with the increasing use of blood tests for rapid diagnostics. Hospitals and ambulatory surgical centers are key end-use industries contributing to market expansion. North America, Asia Pacific, and Europe stand as major regional markets, each characterized by unique factors affecting growth. The competitive landscape showcases the involvement of numerous companies striving to innovate and pioneer advancements in heart attack diagnostics.
Request a customized copy of the report @ https://www.reportsanddata.com/request-customization-form/4132
Thank you for reading our report. To inquire about customization or any query about the report, please get in touch with us. Our team will make sure the report is best suited to your needs.
Browse for more reports:
Peripheral Artery Disease Treatment Market
Diffuse Large B-Cell Lymphoma (DLBCL) Treatment Market
Deep Vein Thrombosis (DVT) Market
WHIM Syndrome Treatment Market
Handheld Ultrasound Devices Market
About Reports and Data
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
Contact Us:
John W
(Head of Business Development)
Reports and Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
Blogs | Press Release | Industry News | Our competencies
Browse More Upcoming Reports @ https://www.reportsanddata.com/upcoming-reports
Browse More Latest Reports @ https://www.reportsanddata.com/report
